Please try another search
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Jay Philip Siegel | 68 | - | Member of Scientific Advisory Board |
Michael C. Milone | - | - | Co-Founder & Co-Chair of Scientific Advisory Board |
Mark J. Simon | 59 | 2018 | Independent Director |
Aimee Payne | - | - | Co-Founder & Co-Chair of Scientific Advisory Board |
Steven A. Nichtberger | 60 | 2017 | Co-Founder, Chairman, CEO & President |
Brian F. Daniels | 62 | 2018 | Member of Scientific Advisory Board |
Drew Weissman | - | 2021 | Member of Scientific Advisory Board |
Georg A. Schett | - | 2022 | Member of Scientific Advisory Board |
Scott C. Brun | 55 | 2021 | Independent Director |
Catherine Bollard | 55 | 2019 | Independent Director |
Iain B. McInnes | 58 | 2020 | Member of Scientific Advisory Board |
Carl H. June | 69 | 2020 | Member of Scientific Advisory Board |
Shawn Cline Tomasello | 64 | 2023 | Independent Director |
Richard C. Henriques | 68 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review